NBT Bank N A NY Has $591,000 Stake in Becton, Dickinson and Company $BDX

NBT Bank N A NY decreased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 12.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,433 shares of the medical instruments supplier’s stock after selling 488 shares during the quarter. NBT Bank N A NY’s holdings in Becton, Dickinson and Company were worth $591,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Saudi Central Bank acquired a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth approximately $26,000. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth approximately $27,000. Alpine Bank Wealth Management acquired a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth approximately $29,000. Cornerstone Planning Group LLC grew its position in shares of Becton, Dickinson and Company by 341.4% during the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after buying an additional 99 shares during the period. Finally, Kelly Lawrence W & Associates Inc. CA acquired a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth approximately $31,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Shares of BDX opened at $193.85 on Thursday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99. The firm’s 50 day moving average price is $189.65 and its two-hundred day moving average price is $186.88. The firm has a market cap of $55.56 billion, a P/E ratio of 34.87, a PEG ratio of 1.50 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, beating analysts’ consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The firm had revenue of $5.51 billion for the quarter, compared to analyst estimates of $5.50 billion. During the same quarter in the previous year, the firm posted $3.50 earnings per share. The business’s revenue was up 10.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th were given a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date of this dividend was Monday, September 8th. Becton, Dickinson and Company’s payout ratio is currently 74.82%.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on BDX. Argus boosted their price objective on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Morgan Stanley boosted their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Wells Fargo & Company boosted their price objective on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a report on Friday, August 8th. Royal Bank Of Canada began coverage on shares of Becton, Dickinson and Company in a report on Thursday, September 25th. They set a “sector perform” rating and a $211.00 price objective for the company. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday. Three analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $205.40.

Insiders Place Their Bets

In other news, EVP Michael David Garrison sold 1,185 shares of the business’s stock in a transaction on Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the sale, the executive vice president owned 4,887 shares of the company’s stock, valued at $881,077.23. The trade was a 19.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Claire Fraser sold 917 shares of the business’s stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the sale, the director directly owned 22,226 shares in the company, valued at approximately $4,167,375. This represents a 3.96% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 3,023 shares of company stock worth $562,036. 0.36% of the stock is currently owned by insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.